Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats

Journal of Spinal Cord Medicine

Volumn 34, Issue 3, 2011, Pages 257-264

  Anik, Ihsan ^a   Kokturk, Sibel ^a   Genc, Hamza ^a   Cabuk, Burak ^b   Koc, Kenan ^a   Yavuz, Sadan ^a   Ceylan, Sureyya ^a   Ceylan, Savas ^a   Kamaci, Levent ^c   Anik, Yonca ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Golcuk Military Hospital   (Turkey)

^c KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Collagen IV; Glial scar formation; Paraplegia; Spinal cord ischemia; TIMP 2

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANEURYSM CLIP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; ARTICLE; BLOOD BRAIN BARRIER; CELL TYPE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GLIA; HYPOXIA; LUMBAR SPINE; MALE; NONHUMAN; RAT; REPERFUSION INJURY; SCAR FORMATION; SPINAL CORD ISCHEMIA;

ANALYSIS OF VARIANCE; ANIMALS; COLLAGEN TYPE I; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; MALE; RATS; RATS, WISTAR; REPERFUSION; SPINAL CORD; SPINAL CORD ISCHEMIA; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 79958000149     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1179/107902611X12972448729648     Document Type: Article

References (55)

1. Erten SF, Kocak A, Ozdemir I, Aydemir S, Colak A, Reeder BS. Protective effect of melatonin on experimental spinal cordischemia. Spinal Cord 2003;4(10):533-38. (Pubitemid 37260326)
2. Emmez H, Yildirim Z, Kale A, Tönge M, Durdaǧ E, Börcek AO, et al. Anti-apoptotic and neuroprotective effects of alpha-lipoic acid on spinal cord ischemia-reperfusion injury in rabbits. Acta Neurochir (Wien) 2010;152(9):1591-600.
3. Baptiste DC, Fehlings MG. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006;23(3-4):318-34. (Pubitemid 43726313)
4. Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala DB, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001;24(5):254-64. (Pubitemid 32906712)
5. Dumont RJ, Verma S, Okonkwo DO, Hurlbert RJ, Boulos PT, Ellegala DB, et al. Acute spinal cord injury, part II: contemporary pharmacotherapy. Clin Neuropharmacol 2001;24(5):265-79. (Pubitemid 32906713)
6. Bowes MP, Swanson S, Zivin JA. The AMPA antagonist LY293558 improves functional neurological outcome following reversible spinal cord ischemia in rabbits. J Cereb Blood Flow Metab 1996;16(5):967-72. (Pubitemid 26292064)
7. Genovese T, Cuzzocrea S.Role of free radicals and poly (ADP-ribose) polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr Med Chem 2008;15(5):477-87. (Pubitemid 351472414)
8. Coselli JS, LeMaire SA, Miller CCR, Schmittling ZC, Köksoy C, Pagan J, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a risk factor analysis. Ann Thorac Surg 2000;69(2):409.
9. Safi HJ, Hess KR, Randel M, Iliopoulos DC, Baldwin JC, Mootha RK, et al. Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. J Vasc Surg 1996;23(2):223.
10. Drinkwater SL, Goebells A, Haydar A, Bourke P, Brown L, Hamady M, et al. On behalf of the Regional Vascular Unit, St Mary's Hospital, Imperial College NHS Trust. The incidence of spinal cord ischaemia following thoracic and thoracoabdominal aortic endovascular intervention. Eur J Vasc Endovasc Surg 2010;40(6):729-35.
11. Pouw MH, Hosman AJ, van Kampen A, Hirschfeld S, Thietje R, van de Meent H. Is the outcome in acute spinal cord ischaemia different from that in traumatic spinal cord injury?Across-sectional analysis of the neurological and functional outcome in a cohort of 93 paraplegics. Spinal Cord 2011;49(2):307-12.
12. Chronidou F, Apostolakis E, Papapostolou I, Grintzalis K, Georgiou CD, Koletsis EN, et al. Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/ reperfusion injury in rabbits. J Cardiothorac Surg 2009;4:50.
13. Cao X, Phillis JW. The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radic Res 1995;23(4):365-70.
14. Hsu JY, McKeon R, Goussev S, Werb Z, Lee JU, Trivedi A, et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 2006;26(39):9841-50. (Pubitemid 44477146)
15. Esposito E, Genovese T, Caminiti R, Bramanti P, Meli R, Cuzzocrea S. Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury. J Pineal Res 2008;45(2):149-56.
16. Buss A, Pech K, Kakulas BA, Martin D, Schoenen J, Noth J, et al. Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurol 2007;7:17.
17. Liesi P, Kauppila T. Induction of type IV collagen and other basement- membrane-associated proteins after spinal cord injury of the adult rat may participate in formation of the glial scar. Exp Neurol 2002;173(1):31-45. (Pubitemid 34081724)
18. Stichel CC, Hermanns S, Luhmann HJ, Lausberg F, Niermann H, D'UrsoD, et al. Inhibition of collagen IV deposition promotes regeneration of injured CNS axons. Eur J Neurosci 1999;11(2):632-46. (Pubitemid 29050465)
19. Iseda T, Nishio T, Kawaguchi S, Kawasaki T, Wakisaka S. Spontaneous regeneration of the corticospinal tract after transection in young rats: collagen type IV deposition and astrocytic scar in the lesion site are not the cause but the effect of failure of regeneration. J Comp Neurol 2003;464(3):343-55. (Pubitemid 36988786)
20. Timpl R, Wiedemann H, Van Delden V, Furthmayr H, Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur Neurol 1981;41(1):35-43.
21. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J 1990;4(6):1577-90.
22. Guo M, Lin V, Davis W, Huang T, Carranza A, Sprague S, et al. Preischemic induction of TNF-alpha by physical exercise reduces blood-brain barrier dysfunction in stroke. J Cereb Blood Flow Metab 2008;28(8):1422-30.
23. Kose N, Asashima T, Muta M, Iizasa H, Sai Y, Terasaki T, et al. Altered expression of basement membrane-related molecules in rat brain pericyte, endothelial, and astrocyte cell lines after transforming growth factor-beta1 treatment. Drug Metab Pharmacokinet 2007;22(4):255-66.
24. Grant DS, Kleinman HK. Regulation of capillary formation by laminin and other components of the extracellular matrix. EXS (Experientia Supplementum) 1997;79:317-33.
25. Tilling T, Engelbertz C, Decker S, Korte D, Huwel S, Galla HJ. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 2002;310(1):19-29.
26. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97(11):1093-107.
27. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18(5):1135-49. (Pubitemid 30123793)
28. La Fleur M, Underwood JL, Rappolee DA, Werb Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J Exp Med 1996;184(6): 2311-26. (Pubitemid 27023731)
29. Shapiro SD. A concise yet informative stroll through matrix metalloproteinases and TIMPs. J Cell Sci 2000;113(Pt 19):3355-6.
30. Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, et al. University of California, San Francisco BAVM Study Group. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenousmalformations. Stroke 2003;34(4):925-31.
31. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998;29(10):2189-95. (Pubitemid 28443538)
32. Webster NL, Crowe SM. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 2006;80(5): 1052-66. (Pubitemid 44646311)
33. Osman M, Tortorella M, Londei M, Quaratino S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase define the migratory characteristics of human monocytederived dendritic cells. Immunology 2002;105(1):73-82. (Pubitemid 34128042)
34. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2(9):657-72. (Pubitemid 37328917)
35. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74(2):111-22. (Pubitemid 27455388)
36. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002;39(3):279-91. Erratum in: Glia 2002;40(1):130.
37. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370(6484):61-5. (Pubitemid 24216953)
38. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270(10):5331-8.
39. Hirano S, Yonezawa T, Hasegawa H, Hattori S, Greenhill NS, Davis PF, et al. Astrocytes express type VIII collagen during the repair process of brain cold injury. Biochem Biophys Res Commun 2004;317(2):437-43. (Pubitemid 38452502)
40. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull 1999;49(6):377-91. (Pubitemid 29385505)
41. Shearer MC, Fawcett JW. The astrocyte/meningeal cell interface - a barrier to successful nerve regeneration. Cell Tissue Res 2001; 305(2):267-73. (Pubitemid 32681903)
42. Eddleston M, Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience 1993;54(1):15-36. (Pubitemid 23147085)
43. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression ofmatrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998; 152(3):729-41. (Pubitemid 28110720)
44. Aoki T, Kataoka H, Moriwaki T, Nozaki K, Hashimoto N. Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms. Stroke 2007;38(8):2337-45. (Pubitemid 47457578)
45. Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, et al. Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 2008;28(10):1674-85.
46. Huhtala P, Humphries MJ, McCarthy JB, Tremble PM, Werb Z, Damsky CH. Cooperative signaling by alpha 5 beta 1 and alpha 4 beta 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 1995;129(3):867-79.
47. Tremble P, Damsky CH, Werb Z. Components of the nuclear signalling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol 1995;129(6):1707-20.
48. Cavdar Z, Oktay G, Egrilmez MY, Genc S, Genc K, Altun Z, et al. In vitro reoxygenation following hypoxia increases MMP-2 and TIMP-2 secretion by human umbilical vein endothelial cells. Acta Biochim Pol 2010;57(1):69-73.
49. Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999;53(1):62-70. (Pubitemid 29329650)
50. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995;26(11):2120-26.
51. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997; 48(4):921-6.
52. Hughes PM, Wells GM, Clements JM, Gearing AJ, Redford EJ, Davies M, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121(Pt3):481-94. (Pubitemid 28116345)
53. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)- induced hemorrhage after thromboembolic stroke. Stroke 2000; 31(12):3034-40.
54. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.Brain 2001;124(Pt 4):1734-42.
55. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood brain barrier by type IV collagenase. Brain Res 1992; 576(2):203-7.